Pediatric Cancer Clinical Trial Finder
We believe that patients and families should have tools available to help make the search for treatments easier. For that reason, we’ve developed a Pediatric Cancer Clinical Trial Navigator for CAR T-cell therapy and other immunotherapy treatments. Use the filters to display relevant trials. Clicking on a card will allow you to access more detailed information, including contact information, for each clinical trial.
Recruiting
Learn More
Genetic
Biological
Drug
iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma (VEGAS)
U.S.
TX
Recruiting
Learn More
Genetic
Biological
Drug
A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma (PLAT-04)
U.S.
WA
Active, not recruiting
Learn More
Genetic
Biological
Drug
Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia (PLAT-03)
U.S.
WA
Recruiting
Learn More
Genetic
Biological
Drug
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas (ATLAS)
U.S.
NC
Recruiting
Learn More
Genetic
Biological
Drug
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT (CARPASCIO)
U.S.
TX
Recruiting
Learn More
Genetic
Biological
Drug
CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM (HERT-GBM)
U.S.
TX
Completed
Learn More
Genetic
Biological
Drug
Administration of T Lymphocytes for Hodgkin’s Lymphoma and Non-Hodgkin’s Lymphoma (CART CD30)
U.S.
NC,
TX
Active, not recruiting
Learn More
Genetic
Biological
Drug
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma (GAIL-N)
U.S.
TX
Recruiting
Learn More
Genetic
Biological
Drug
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
U.S.
TN
Recruiting
Learn More
Genetic
Biological
Drug
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia (PLAT-02)
U.S.
CA,
WA
Recruiting
Learn More
Genetic
Biological
Drug
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
U.S.
WA
Recruiting
Learn More